Review of Studies Conducted on Personalized Medicine: Swot Analysis

Öz

Personalized medicine is an approach in which personalized treatment is provided to individuals by taking into account their genetic structure, environmental factors and lifestyles. The main purpose of this approach is to develop more effective and personalized solutions to prevent and treat diseases. In this context, the aim of the study was to conduct a SWOT analysis of the studies obtained on personalized medicine. Bibliometric analysis was used while obtaining the studies. Articles were obtained by searching the keywords “personalized” or “medicine” and “healthcare”, “management” in the Web of Science database between 1994-2023. The quality of the 21 articles obtained was assessed and SWOT analysis was performed on these articles. As a result of the SWOT analysis, the strengths of personalized medicine, such as facilitating the management of chronic diseases and increasing quality and safety; and the weaknesses, such as the disruption of communication between healthcare personnel and patients and the violation of confidentiality of medical information, were reached. Personalized medicine creates many opportunities such as increasing interest in digital technologies and ensuring patient-centeredness. In addition, individuals are faced with threats such as inadequate health literacy and reluctance to make health-related payments due to increasing costs.

Anahtar Kelimeler

• Personalized Medicine
• Bibliometric Analysis
• Healthcare Management

Kişiselleştirilmiş Tıbba Yönelik Yapılan Çalışmaların İncelenmesi: SWOT Analizi

Öz

Kişiselleştirilmiş tıp, bireylerin genetik yapılarının, çevresel faktörlerinin ve yaşam tarzlarının dikkate alınarak bireylere yönelik özelleştirilmiş tedavinin sunulduğu yaklaşımdır. Bu yaklaşımın temel amacı hastalıkları önlemek ve tedavi etmek için daha etkili ve kişiye özel çözümler geliştirmektir. Bu doğrultuda çalışmada kişiselleştirilmiş tıbba dair elde edilen çalışmaların SWOT analizinin yapılması hedeflenmiştir. Çalışmalar elde edilirken bibliyometrik analizden yararlanılmıştır. 1994-2023 yılları arasında Web of Science veri tabanında “personalized” or “medicine” and “healthcare”, “management” anahtar kelimeleri aratılarak makaleler elde edilmiştir. Elde edilen 21 makalenin kalite değerlendirilmesi yapılmış, bu makaleler üzerinden SWOT analizi gerçekleştirilmiştir. Yapılan SWOT analizi sonucunda kişiselleştirilmiş tıbbın kronik hastalıkların yönetimini kolaylaştırma, kalite ve güvenliği artırma gibi güçlü; sağlık personeli ve hasta arasındaki iletişimin bozulması ve tıbbi bilgilerinin gizlilik ihlali gibi zayıf yönlerine ulaşılmıştır. Kişiselleştirilmiş tıp, dijital teknolojilere duyulan ilginin artması ve hasta merkezliliği sağlama gibi birçok fırsat yaratmaktadır. Bunun yanı sıra bireylerin yetersiz sağlık okuryazarlığına sahip olması ve maliyetlerin artmasına bağlı olarak sağlıkla ilgili ödemelerde isteksizlik gibi tehditlerle karşı karşıya gelinmektedir.

Anahtar Kelimeler

• Kişiselleştirilmiş Tıp
• Bibliyometrik Analiz
• Sağlık Yönetimi

Kaynakça

1. Bashyam, M. D., & Hasnain, S. E. (2003). The human genome sequence: impact on health care. Indian Journal of Medical Research, 117, 43-65.
2. Baskın, Y. (2007). Changes in concepts of the technological progress: personalized medicine. Türk Hijyen ve Deneysel Biyoloji Dergisi, 64(2), 54-59.
3. Broadus, R. N. (1987). Toward a definition of “bibliometrics”. Scientometrics, 12, 373-379.
4. Bulut, A., & Şengül, H. (2023). Kişiselleştirilmiş tıp envanterinin geliştirilmesi: geçerlik ve güvenirlik çalışması. Socıal Scıences Studıes Journal, 9(115), 8421-8434.
5. Carrasco Ramiro, F., Peiró-Pastor, R., & Aguado, B. (2017). Human genomics projects and precision medicine. Gene therapy, 24(9), 551-561.
6. Cho, S. H., Jeon, J., & Kim, S. I. (2012). Personalized medicine in breast cancer: a systematic review. Journal of breast cancer, 15(3), 265-272.
7. Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., & Skaar, T. C. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clinical Pharmacology & Therapeutics, 91(2), 321-326.
8. Currie, G., & Delles, C. (2018). Precision medicine and personalized medicine in cardiovascular disease. Sex-Specific Analysis of Cardiovascular Function, 589-605.

9. Dalbayrak, B., & Metiner, M. D. (2022). Personalized medicine: a solution for today and tomorrow. European Journal of Biology, 81(2), 267-273.
10. Frueh, F. W. & Gurwitz, D. (2004). From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics, 5(5), 571–579.
11. Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S., & Schulman, K. A. (2005). Implications of pharmacogenomics for drug development and clinical practice. Archives of Internal Medicine, 165(20), 2331. doi:10.1001/archinte.165.20.2331
12. Goetz, L. H., ve Schork, N. J. (2018). Personalized medicine: motivation, challenges, and progress. Fertility and sterility, 109(6), 952-963. https://doi.org/10.1016/j.fertnstert.2018.05.006
13. Gubert, L. C., da Costa, C. A., & Righi, R. D. R. (2020). Context awareness in healthcare: a systematic literature review. Universal Access in the Information Society, 19(2), 245-259.
14. Gürel, E. ve Tat, M. (2017). Swot Analysis: A Theoretical Review. Uluslararası Sosyal Araştırmalar Dergisi, 10(51), 994-1006.
15. Hein, A.E., Vrijens, B., & Hiligsmann, M. (2020). A Digital Innovation for the Personalized Management of Adherence: Analysis of Strengths, Weaknesses, Opportunities, and Threats. Frontiers in Medical Technology, 2, 1015.
16. Jain, K. K. (2002). Personalized medicine. Current Opinion in Molecular Therapeutics, 4(6), 548-558.
17. Joly, Y., Saulnier, K. M., Osien, G., & Knoppers, B. M. (2014). The ethical framing of personalized medicine. Current Opinion in Allergy and Clinical Immunology, 14(5), 404-408.
18. Kapelner, A., Bleich, J., Levine, A., Cohen, Z. D., DeRubeis, R. J., & Berk, R. (2021). Evaluating the effectiveness of personalized medicine with software. Frontiers in Big Data, 4, 1019.
19. Kawamoto, K., Lobach, D. F., Willard, H. F., & Ginsburg, G. S. (2009). A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Medical Informatics and Decision Making, 9(1), 1014.
20. Kitchenham, B. (2004). Procedures for performing systematic reviews. Keele, UK, Keele University, 33(2004), 1-26. Konar, N. M., Karaismailoglu, S., & Karaismailoglu, E. (2022). Status and trends of personalized medicine research from 2000 to 2020: a bibliometric analysis. Current Medical Research and Opinion, 38(5), 837-846.
21. Kushner, J. (2014). The ethics of personalized medicine. Personalized Medicine Universe, 3, 42-45.
22. Le Texier, V., Henda, N., Cox, S., & Saintigny, P. (2019). Data sharing in the era of precision medicine: a scientometric analysis. Precision Cancer Medicine, 2, 1015.
23. Liu, M., Yang, F., & Xu, Y. (2022). Global trends of stem cell precision medicine research (2018–2022): A bibliometric analysis. Frontiers in Surgery, 9, 1014.
24. Mishra, V., Chanda, P., Tambuwala, M. M., & Suttee, A. (2019). Personalized medicine: An overview. International Journal of Pharmaceutical Quality Assurance, 10(2), 290-294.
25. Moura, I., Teles, A., Silva, F., Viana, D., Coutinho, L., Barros, F., & Endler, M. (2020). Mental health ubiquitous monitoring supported by social situation awareness: A systematic review. Journal of biomedical informatics, 107, 103454.
26. O’Donnell, J. C. (2013). Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value in Health, 16(6), 1-3.
27. Overby, C. L., & Tarczy-Hornoch, P. (2013). Personalized medicine: challenges and opportunities for translational bioinformatics. Personalized medicine, 10(5), 453-462.
28. Parens, E. (2015). Drifting away from informed consent in the era of personalized medicine. Hastings Center Report, 45(4), 16-20.
29. Personalized Medicine Coalition (PMC). (2015) The Case for Personalized Medicine. http://www.personalizedmedicinecoalition.org adresinden 06.06.2019 tarihinde alınmıştır.
30. Pot, M., Brehme, M., El0Heliebi, A., Gschmeidler, B., Hofer, P., Kroneis, T., Schirmer, M., Schumann, S., & Prainsack, B. (2020). Personalized medicine in Austria: expectations and limitations. Personalized Medicine, 17(6), 423-428. https://doi.org/10.2217/pme0202000061
31. Pravin, B., Kishor, O., & Ashwini, B. (2021). Personalized medicine: the future of modern medicine. Authorea Preprints, 3, 109.
32. Richmond, T. D. (2008). The current status and future potential of personalized diagnostics: Streamlining a customized process. Biotechnology Annual Review, 14, 411-422.
33. Robert, G., de la Taille, A., & Descazeaud, A. (2018). La médecine personnalisée gagne du terrain. Progrès en urologie, 28(15), 797-798.
34. Sağlık İstatistik Yıllığı. (2023). https://www.saglik.gov.tr/TR-84930/saglik-istatistikleri-yilliklari.html adresinden 06.06.2019 tarihinde alınmıştır.
35. Scheuner, M. T., Sieverding, P., & Shekelle, P. G. (2008). Delivery of genomic medicine for common chronic adult diseases: a systematic review. Jama, 299(11), 1320-1334.
36. Schleidgen, S., Klingler, C., Bertram, T., Rogowski, W. H., & Marckmann, G. (2013). What is personalized medicine: sharpening a vague term based on a systematic literature review. Bmc Medical Ethics, 14(1), 1012.
37. Sigman M. (2018). Introduction: Personalized medicine: what is it and what are the challenges?. Fertility and sterility, 109(6), 944–945. https://doi.org/10.1016/j.fertnstert.2018.04.027
38. Snyderman, R. (2011). Personalized health care: from theory to practice. Biotechnology journal, 7(8), 973-979.
39. Tekpınar, L., & Erdem, R. (2019). Kişiselleştirilmiş tıp ve genom araştırmalarının sağlık çıktıları bağlamında değerlendirilmesi. Hacettepe Sağlık İdaresi Dergisi, 22(4), 843-862.
40. Van Eck, N. J. (2011). Methodological advances in bibliometric mapping of science (No. EPS0201102470LIS).
41. Vicente, A. M., Ballensiefen, W., & Jönsson, J. I. (2020). How personalised medicine will transform healthcare by 2030: the ICPerMed vision. Journal of translational medicine, 18(1), 180. https://doi.org/10.1186/s1296700200023160w
42. West, M., Ginsburg, G. S., Huang, A. T., & Nevins, J. R. (2006). Embracing the complexity of genomic data for personalized medicine. Genome research, 16(5), 559-566.
43. Willard, H. F., Angrist, M., & Ginsburg, G. S. (2005). Genomic medicine: genetic variation and its impact on the future of health care. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 360(1460), 1543-1550.
44. Williams, J. R., Lorenzo, D., Salerno, J., Yeh, V. M., Mitrani, V. B., & Kripalani, S. (2019). Current applications of precision medicine: a bibliometric analysis. Personalized medicine, 16(4), 351-359.
45. Wolf, S. M., Crock, B. N., Van Ness, B., Lawrenz, F., Kahn, J. P., Beskow, L. M., & Wolf, W. A. (2012). Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genetics in Medicine, 14(4), 361-384.